GDPD3 and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, at 40–60 days post-BMT in mice treated with dasatinib, the frequency of BCR-ABL1/EGFP+ leukaemia cells was significantly decreased in PB of Gdpd3−/− retro-CML-affected mice compared to PB of Gdpd3+/+ retro-CML-affected mice (Fig. 6c).